Ariad leukemia drug helps 47 percent of patient: study
(Reuters) – air max shoes Early results from a pivotal trial of Ariad Pharmaceuticals Inc’s experimental leukemia drug ponatinib show it is effective in nearly half of patients who had stopped responding to currently available drugs
The trial involves 449 patients — the interim results are from 392 subjects — air max sale who had stopped responding to treatment with Sprycel, sold by Novartis AG, and Bristol-Myers Squibb Co’s Tasigna.
Both of these older drugs, respectively known generically as dasatinib and nilotinib, are members of a class called tyrosine kinase inhibitors.
Ariad plans to file for U.S. regulatory approval of ponatinib in mid-2012 based on the mid-stage trial results.
Berger said the company will decide in the first quarter of next year whether to secure a European partner for the drug, and remains committed to commercializing it on its own in the United States.
Ariad plans to file for U.S. regulatory approval of ponatinib in mid-2012 based on the mid-stage trial results.
Processing your request, Please wait....
